# Investigating the Safety and Efficacy of SHR6508 Injection in the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients : A Multicenter, Long-term Clinical Trial

> **NCT06236295** · PHASE2 · UNKNOWN · sponsor: **Shanghai Hengrui Pharmaceutical Co., Ltd.** · enrollment: 303 (actual)

## Conditions studied

- Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis

## Interventions

- **DRUG:** SHR6508

## Key facts

- **NCT ID:** NCT06236295
- **Lead sponsor:** Shanghai Hengrui Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-02-20
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 303 (ACTUAL)
- **Last updated:** 2024-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06236295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06236295, "Investigating the Safety and Efficacy of SHR6508 Injection in the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients : A Multicenter, Long-term Clinical Trial". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06236295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*